AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 149%
Price (€) 4.72
Market Cap (€M) 172
Perf. 1W: 7.40%
Perf. 1M: 5.48%
Perf. 3M: 16.7%
Perf Ytd: 43.1%
10 day relative perf. to stoxx600: 4.49%
20 day relative perf. to stoxx600: 1.61%
EPS change26/09/2022

Minor changes after H1 22

Change in EPS2022 : € -0.32 vs -0.23ns
2023 : € -0.35 vs -0.25ns

We have only changed our short-term estimates after the release of the H1 22 results. These changes are minor and are limited to FY23-24) even if they look more significant in EPS terms due to the fact that the result is a small loss, implying that any change to our numbers translates into an apparent bigger change in percentage terms. The impact on our valuation of the stock is thus marginal.



.